ROLE OF MONOCLONAL ANTIBODIES IN THE TREATMENT OF ASTHMA

Paul M O’Byrne MB

BACKGROUND: Patients with severe refractory asthma represent a small subset of the asthmatic population (between 5% and 10% of all patients) but are the greatest burden to the health care system. New treatment approaches developed to manage some of the phenotypes of severe refractory asthma have included humanized monoclonal antibodies (hMabs).

OBJECTIVE: To review the evidence and ascertain whether hMabs provide clinical benefit to patients with severe refractory asthma.

METHODS: Studies that examined the efficacy of hMabs against immunoglobulin (Ig) E, tumour necrosis factor-alpha, interleukin (IL)-5, and IL-4/IL-13 in patients with severe refractory asthma were reviewed and summarized.

RESULTS: Treatment with anti-IgE improved asthma control and reduced severe exacerbations in patients with severe asthma and elevated serum IgE levels. Treatments with hMabs that block tumour necrosis factor-alpha are unlikely to be useful in asthma treatment. In contrast, hMabs that block IL-5 have consistently shown benefit in reducing severe exacerbations in patients with severe refractory asthma with persistent eosinophilia. Finally, hMabs that block IL-13 may provide benefit in patients with elevated blood eosinophil levels.

DISCUSSION: hMabs that block IgE are approved for the treatment of allergic asthma. It is likely that blocking IL-5 will also provide benefit in patients with severe asthma with persistent eosinophilia. These studies have emphasized the importance of careful phenotyping of patients with severe refractory asthma before embarking on treatment with hMabs.

Key Words: Interleukin-5; Interleukin-13; Severe asthma

Despite the availability of very effective and safe medications to treat asthma (1), surveys of asthma patient populations indicate that the majority of patients are not fully controlled (2). This lack of asthma control may be due to a variety of factors, including poor adherence to treatment (the most common cause), psychosocial factors, vocal cord dysfunction, persistent exposure to allergens or toxic substances, or undertreated co morbidities. However, a proportion of these patients can be considered to have severe refractory asthma (3).

Patients with severe refractory asthma represent a small subset of the asthmatic population (between 5% and 10% of all patients) but are the greatest burden to the health care system in Canada (4) and elsewhere, and are the patient population most in need of new treatment approaches. Efforts have been undertaken to phenotype patients with severe refractory asthma, which have included unbiased cluster analyses (5) and phenotyping based on the type of airway inflammatory cells (6). It has, however, become clear that no single phenotype can explain all severe refractory asthma and no single treatment approach will improve asthma control in all patients with severe disease.

New treatment approaches developed to manage some of the phenotypes of severe refractory asthma have included humanized monoclonal antibodies (hMabs) against immunoglobulin (Ig) E, or specific cytokines known to be important in the initiation or persistence of asthmatic inflammation. A large number of hMabs have been evaluated in preclinical models of allergic asthma. The present article reviews selected studies that have evaluated the efficacy of hMabs in severe refractory asthma.

ANTI-IgE hMAB

An hMab that blocked binding of IgE to its receptor (FcεR1) (omalizumab) was the initial hMab to demonstrate efficacy in asthma and is now recommended in asthma guidelines as a treatment option for patients with severe refractory asthma (1). Several studies have demonstrated that omalizumab improves asthma control and reduces severe exacerbations in both adults (7) and children (8) with severe disease and elevated serum IgE levels. Interestingly, the benefit demonstrated in children was predominantly apparent during the autumn asthma exacerbation peak.

ANTITUMOUR NECROSIS FACTOR-ALPHA hMABs

The management of several chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, has been revolutionized by the availability of hMabs that block the action of tumour necrosis factor-alpha (TNF-α). Early studies in asthma involving selected patients with elevated TNF-α levels in bronchoalveolar lavage fluid or an increased expression of membrane-bound
in a reduction in the number of blood and airway eosinophils to within the normal range. Furthermore, treatment enabled a reduction of oral corticosteroids, reduced the number of severe asthma exacerbations, improved forced expiratory volume in 1 s (FEV₁) and measures of asthma control (15). This benefit of mepolizumab has also been shown in asthmatic patients with refractory asthma, but not requiring oral corticosteroids to manage their airway eosinophilia (16) and in a larger study involving selected patients with increased blood eosinophil levels (17) (Figure 1). Subsequently, treatment with reslizumab has demonstrated benefits in improving FEV₁ and asthma control, again in patients with severe refractory asthma and persisting airway eosinophilia (18). A third hMab against IL-5 (benzlizumab), which binds to the IL-5 receptor, is also in clinical trials involving patients with severe asthma. The magnitude of benefit in reducing severe asthma exacerbations that these hMabs have consistently demonstrated in patients with severe refractory asthma and persisting airway eosinophilia, make it very likely that they will be a useful therapeutic option for patients of this specific phenotype.

**ANTI-IL-4/IL-13 hMABs**

Both IL-4 and IL-13 are important cytokines in the initiation and persistence of allergic airway inflammation. They have been demonstrated to be necessary for IgE production, mucus gland hyperplasia, eosinophilic airway inflammation and airway hyper-responsiveness. These cytokines act through receptors that share a common alpha-chain (IL-4Rα), which can bind either IL-4 or IL-13. Several approaches have been used to block the activation of these receptors. One approach has been to develop an IL-4 variant – a ‘mutene’ molecule – that inhibits binding of IL-4 and IL-13 to IL-4Rα. This molecule has been shown to attenuate allergen-induced late asthmatic responses in subjects with asthma (19). In addition, hMabs that prevent binding of IL-4 or IL-13 to their receptors have also been developed. One study involving allergic asthmatic subjects (20) has shown that an hMab that prevents binding of IL-13 to IL-4Rα, but not an hMab that prevents binding of IL-13 to IL-13Rα (the remaining component of the IL-13 receptor) or IL-3Rα2 (which may be a natural antagonist of IL-13), also attenuates allergen-induced early and late asthmatic responses, but not allergen-induced eosinophilic airway inflammation nor airway hyper-responsiveness. Studies involving patients with persistent asthma have yielded interesting results. In one study, treatment with an hMab, which prevents binding of IL-4 and IL-13 to IL-4Rα, did not demonstrate significant benefit in improving lung function or asthma control, but did show a trend in reducing asthma exacerbations (21). Interestingly, some benefit was apparent in patients with the most poorly controlled asthma. Another study, involving patients with severe refractory asthma (22), reported that an antibody that binds to IL-13 and prevents its attachment to the IL-4/IL-13 receptor complex did not significantly improve FEV₁ values in the patient population as a whole but did provide a significant and clinically useful improvement in patients with high blood perisinus levels. Periostin, a protein component of subepithelial fibrosis, is released from epithelial cells following stimulation by IL-13 (23). The periostin gene has been identified as being upregulated in epithelial cells of asthma patients (24).

**CONCLUSIONS**

The use of hMabs to treat asthma was supported by evidence of the efficacy of omalizumab in patients with allergic asthma and its subsequent approval by drug regulatory agencies worldwide. There is convincing evidence supporting the benefit of anti-IL-5 hMabs in patients with severe refractory asthma and persisting airway eosinophilia, and it is highly likely that these hMabs will be helpful in the management of this phenotype of severe asthma. Treatment approaches to block IL-13 activation of its receptor are also showing promise in patients with an enhanced IL-13 phenotype reflected by high blood perisinus levels. Collectively, these studies have emphasized the importance of careful phenotyping of patients with severe refractory asthma before embarking on treatment with hMabs.
REFERENCES